A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT).

ABSTRACT:

Background

REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan.

Objectives

The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral corticosteroids (OCS) or emergency department (ED) visits and/or hospitalizations) in the 12 months pre- and post-mepolizumab treatment. Secondary objectives assessed changes in the number of CSEs requiring ED visits/hospitalizations and daily maintenance OCS (mOCS) dosage 12 months pre- and post-mepolizumab treatment. Three- and four-component clinical remissions were analyzed based on OCS-free, exacerbation-free, and asthma control (± stability in lung function).

Design

REMIT was a retrospective, observational, self-controlled

SUBMITTER: Cheng SL 

PROVIDER: S-EPMC11744627 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature